{"id":"adjuvant-non-live-rsv-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated or recombinant RSV antigens combined with an adjuvant to enhance immune response. The adjuvant amplifies the body's innate immune activation, promoting stronger and more durable antibody production and T-cell responses against RSV. This approach aims to provide protection against RSV infection while avoiding the safety concerns associated with live attenuated vaccines.","oneSentence":"An adjuvanted non-live RSV vaccine stimulates the immune system to produce antibodies and cellular immunity against respiratory syncytial virus without containing live virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:12.655Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"RSV infection prevention in adults (Phase 3)"}]},"trialDetails":[{"nctId":"NCT06593210","phase":"PHASE3","title":"RSV Vaccine in Transplant Recipients","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-10-01","conditions":"Vaccine Response Impaired, Respiratory Syncytial Virus Infections, Immune Suppression","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Arexvy"],"phase":"phase_3","status":"active","brandName":"Adjuvant, non-live RSV vaccine","genericName":"Adjuvant, non-live RSV vaccine","companyName":"University Health Network, Toronto","companyId":"university-health-network-toronto","modality":"Biologic","firstApprovalDate":"","aiSummary":"An adjuvanted non-live RSV vaccine stimulates the immune system to produce antibodies and cellular immunity against respiratory syncytial virus without containing live virus. Used for RSV infection prevention in adults (Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}